CJC-1295 with DAC is a long-acting GHRH analog intended for controlled laboratory work. It is studied in experimental systems involving extended growth-hormone signaling, pharmacokinetics, and GH/IGF-1-axis models. Descriptions of research pathways do not establish safety, effectiveness, or suitability for human or veterinary use.
Research areas include:
• Extended GHRH-receptor activation
• Growth-hormone and IGF-1 response profiles
• Drug-affinity-complex pharmacokinetics
• Pituitary and endocrine feedback models
Research limitations and safety:
• Published evidence and human safety data may be limited; composition, identity, purity, and experimental controls should be independently verified. Published or regulatory sources identify material safety uncertainties or adverse signals requiring particular caution.
• No dosing, administration, or therapeutic-use guidance is provided.
being sold for research only.





Reviews
There are no reviews yet.